Industry Experts on Drug Development and Genetic Testing Announced for BIO’s CEO & Investor Conference

WASHINGTON, D.C. (February 11, 2003)—The Biotechnology Industry Organization (BIO) today announced an array of industry experts that will discuss the future of the biotech investment landscape at the CEO & Investor Conference at the Waldorf-Astoria in New York, Feb. 25-27. Speakers will headline two plenary panel sessions outlining specific issues the biotechnology industry will face in 2003.

WHAT:   The Challenge of Drug Development: Winning Strategies for Building and Maintaining Successful Pipelines
WHEN:   Wednesday, Feb. 26, 8:00—9:30 a.m.
WHERE:   Waldorf-Astoria, Grand Ballroom
WHO:   Bruce Jenett, co-chair of Heller Ehrman’s Life Sciences National Practice Group (moderator)
Roger M. Perlmutter, M.D., Ph.D., executive vice president for R&D, Amgen
Richard DiMarchi, Ph.D., group vice president, Eli Lilly and Company
Seán P. Lance, CEO and chairman of the board, Chiron
Vicki L. Sato, Ph.D., president, Vertex Pharmaceuticals, Inc.
WHAT:   How Will Health Plans Treat Genetic Testing: The Distance Between Diagnostics and Therapy
WHEN:   Thursday, Feb. 27, 8—9:30 a.m.
WHERE:   Waldorf-Astoria, Grand Ballroom
WHO:   John Rowe, M.D., president and CEO, Aetna Health Plans
James Robinson, Ph.D., associate professor, Health Economics, University of California—Berkeley
Paul Billings, M.D., Ph.D., vice president, Wipro, Inc.
Robert Cook-Deegan, M.D., director of the Center for Genome Ethics, Law, and Policy, Duke University

For more information on the BIO CEO & Investor Conference, please visit Press registration is complimentary for credentialed members of the news media. Press releases, conference updates and registration information are posted in the “Media” section of the conference Web site.

BIO represents more than 1,000 biotechnology companies, academic institutions, state biotechnology centers and related organizations in all 50 U.S. states and 33 other nations. BIO members are involved in the research and development of health-care, agricultural, industrial and environmental biotechnology products.

# # #